logo image
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Opinion
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
  • SlatorCon
    • London 2019
    • — Divider —
    • Other Events
  • Jobs
  • Directory
  • RFP Center
MENU
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Opinion
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
  • SlatorCon
    • London 2019
    • — Divider —
    • Other Events
  • Jobs
  • Directory
  • RFP Center

  • Partner with Slator
  • Login
Advertisement
Takeaways from Slator Executive Roundtable on China’s Drug Approval Reforms

3 years ago

July 20, 2016

Takeaways from Slator Executive Roundtable on China’s Drug Approval Reforms

Sponsored Content ·

by Slator

On July 20, 2016

3 years ago
Sponsored Content ·

by Slator

On July 20, 2016

Takeaways from Slator Executive Roundtable on China’s Drug Approval Reforms

China has embarked on the biggest regulatory overhaul of its pharmaceutical industry in more than 15 years. Among the drivers of change is Bi Jingquan, who was appointed Director of the China Food and Drug Administration (CFDA) in 2015.

The reform frenzy involving the launch of a full 22 new policies kicked off on April 24, 2015. China’s all-powerful Standing Committee approved a revision to the country’s Drug Administration Law, which forms the central piece of legislation governing the Chinese pharmaceutical industry. The revision removed preapproval requirements for drug companies and lifted state price controls on drugs.

On November 11, 2015, a CFDA circular was issued aiming to expand fast-track approval of new drugs and simplify clinical trials. On March 23, 2016, the CFDA published the first update to its medical device clinical trial guidance in 12 years, which asked companies to strengthen the informed consent process and increase the safety and efficacy of trials.

Advertisement

To discuss the reforms and their impact on the day-to-day operations of large pharmaceutical companies, medical device manufacturers, and clinical research organizations, Slator hosted an executive roundtable on July 12, 2016, in Shanghai.

Shangri-La Shanghai, the venue
Shangri-La Shanghai, the venue

The roundtable was sponsored by Lionbridge, one of the largest global providers of language services for the life sciences industry. Slator was pleased to welcome David Lv from Chinese law firm Global Law Office and a former official of the Shanghai Food and Drug Administration as expert speaker.

Participants included senior executives in operations and regulatory positions from leading pharma companies such as AstraZeneca, United Therapeutics, Boehringer-Ingelheim, Sanofi, Parexel, Novartis, Pfizer, Abbott, and China-based WuXi AppTec.

Speaker David Lv began by giving an overview of regulatory agencies at state, provincial, and local levels, which are involved in setting and executing policy in China. He continued by discussing the regulatory philosophy of previous and current CFDA directors that drives decision-making.

After providing a detailed glimpse into some of the core elements of recent regulatory reforms, Lv proceeded to share his unique insights as a former regulator on what companies can expect during onsite inspections. In fact, he shared that unannounced inspections are among the key new features of recently enacted reforms.

Some participants enjoying lunch
Some participants enjoying lunch

Lv concluded the discussion by providing a cautionary tale of a clinical trial gone wrong, where inadequate reporting and delayed action on adverse findings resulted in the revocation of the company’s license and even the filing of criminal charges against key employees.

Due to its sensitive nature, the roundtable was off-the-record and we are unable to go further into details of the lively discussion that took place between participants and the speaker. We can disclose, however, that participants pointed out document management and translation are key challenges in their daily operations, which will only intensify in days to come given the flurry of recent reforms.

Get in touch if you would like to know more about Slator Roundtables

TAGS

clinical researchclinical trial
SHARE
Slator

By Slator

Slator makes business sense of the language services and technology industry with news on the people and deals that shape the industry.

Advertisement

SUSCRIBE TO THE SLATOR WEEKLY

Language Industry Intelligence
In Your Inbox. Every Friday

PUBLISH

PRESS RELEASEJOB AD

SUBSCRIBE

RFP Center
Advertisement

Featured Reports

See all
Slator 2018 Language Industry M&A and Funding Report

Slator 2018 Language Industry M&A and Funding Report

by Slator

Slator 2019 Neural Machine Translation Report—Deploying NMT in Operations

Slator 2019 Neural Machine Translation Report—Deploying NMT in Operations

by Slator

Slator 2018 Blockchain and Translation Report

Slator 2018 Blockchain and Translation Report

by Slator

Slator 2018 Media Localization Report

Slator 2018 Media Localization Report

by Slator

Press Releases

See all
Across Systems Presents New Major Release of its Across Language Server

Across Systems Presents New Major Release of its Across Language Server

by Across Systems GmbH

Smartling Announces 2019 Merger and Acquisition Strategy

Smartling Announces 2019 Merger and Acquisition Strategy

by Smartling

memoQ #1 TMS on SaaS 1000 Growth List

memoQ #1 TMS on SaaS 1000 Growth List

by memoQ

Popular articles

Inside the Brain of a Simultaneous Interpreter, Literally

Inside the Brain of a Simultaneous Interpreter, Literally

by Gino Diño

Why Netflix Shut Down Its Translation Portal Hermes

Why Netflix Shut Down Its Translation Portal Hermes

by Esther Bond

Lionbridge Acquires Gengo to Bolster AI Business

Lionbridge Acquires Gengo to Bolster AI Business

by Florian Faes

Upcoming Events

See All
  1. Translation Conference 2019 Warsaw
    Warsaw, Poland

    The Translation and Localization Conference 2019

    Sobieski Radisson Blu Hotel

    by TLC Conferences

    · March 29 - March 30

    Join the Translation and Localization Conference on 29-30 March 2019 in Warsaw, Poland

    More info €65-370

Featured Companies

See all
Locaria

Locaria

Donnelley Language Solutions

Donnelley Language Solutions

Seprotec

Seprotec

Versacom

Versacom

KERN Global Language Services

KERN Global Language Services

SDL

SDL

Smartling

Smartling

Lingotek

Lingotek

XTM International

XTM International

Smartcat

Smartcat

Memsource

Memsource

Translators without Borders

Translators without Borders

Wordbee

Wordbee

STAR Group

STAR Group

memoQ Translation Technologies

memoQ Translation Technologies

Translia

Translia

Welocalize

Welocalize

Advertisement

Featured Jobs

See all
Senior Manager of Talent Acquisition

Senior Manager of Talent Acquisition

Burbank, CA, United States

Lead Generation Manager (North America)

Lead Generation Manager (North America)

North America

Business Development Manager – (Remote Considered)

Business Development Manager – (Remote Considered)

Santa Barbara, CA, United States

connect with us

footer logo

Slator makes business sense of the language services and technology market.

Our Company

  • Support
  • About us
  • Terms & Conditions
  • Privacy Policy

Suscribe to the Slator Weekly

Language Industry Intelligence
In Your Inbox. Every Friday

© 2019 Slator. All rights reserved.

Join Our Mailing List

Sign up for our Weekly Newsletter and Language Industry Updates Delivered Straight To Your Inbox.

This information will never be shared with third parties. No Spam.